Clinical Trial Results:
A randomized, double-masked, active-controlled, multicenter study comparing the efficacy and safety of ranibizumab (0.3 mg and 0.5 mg) administered as two dosing regimens in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration
Summary
|
|
EudraCT number |
2005-003517-33 |
Trial protocol |
HU AT DE ES PT GB CZ IT BE FI SE GR |
Global completion date |
09 Jan 2008
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
21 Apr 2016
|
First version publication date |
21 Apr 2016
|
Other versions |
|
Summary report(s) |
CRFB002A2302_CT_gov_results |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.